Bulk Pharma Group B
ID: 75A50325R00003Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSEASPR/ORM-SNSAtlanta, GA, 30341, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
  1. 1
    Posted Jan 3, 2025, 12:00 AM UTC
  2. 2
    Updated Jan 3, 2025, 12:00 AM UTC
  3. 3
    Due Jan 17, 2025, 7:00 PM UTC
Description

The Department of Health and Human Services (HHS) is seeking proposals for the procurement of a range of FDA-approved pharmaceuticals as part of the Bulk Pharma Group B initiative. The contract will require the delivery of specific injectable medications, including Acyclovir Sodium, Doxycycline, Levophed, Meropenem, Sodium Chloride, and sterile water, with quantities detailed in the attached Request for Proposal (RFP). This procurement is critical for maintaining the Strategic National Stockpile, ensuring a reliable supply of essential pharmaceuticals for disaster preparedness and response efforts. Interested vendors must submit their proposals by the specified deadline, and inquiries can be directed to primary contact Terri Reed at terri.reed@hhs.gov or secondary contact Kimberly Golden at kimberly.golden1@hhs.gov.

Point(s) of Contact
Files
Title
Posted
Jan 3, 2025, 4:04 PM UTC
The document is a combined synopsis and solicitation for a federal government contract issued by the U.S. Department of Health and Human Services (HHS). The primary purpose is to procure pharmaceutical supplies for the Strategic National Stockpile, aimed at replenishing expired products. The solicitation number is 75A50325R00003, and it anticipates awarding a Firm Fixed Price type contract. There will be a base ordering period of 12 months, with four optional periods of the same duration. The acquisition is conducted under full and open competition and is not set aside for small businesses, with key details outlined including delivery locations and acceptance protocols. Supplementary sections detail the scope of supplies, evaluation criteria, and provisions necessary for contractor compliance, including specific terms related to performance evaluation, payment processing through electronic systems, and record-keeping obligations. Companies are required to submit proposals by the specified deadline, including a completed set of representations and certifications. Overall, this document lays the groundwork for the procurement process, emphasizing the necessity of pharmaceuticals in disaster preparedness and response efforts while adhering to existing federal regulations.
The document pertains to the federal RFP (Request for Proposal) 75A50325R00003, focusing on the procurement of specific pharmaceutical products for the Bulk Pharma Group B. It outlines the technical specifications for various injectable medications including Acyclovir Sodium, Doxycycline, Levophed, Meropenem, Sodium Chloride, and sterile water for injection, designated for delivery over multiple option years. Suppliers are required to specify their company name, business size, and provide detailed information about product packaging, including National Drug Code (NDC) and National Stock Number (NSN) where applicable. The file also requests past performance details from bidders, highlighting the necessity of demonstrating relevant experience in similar projects within the last three years. It emphasizes providing comprehensive project descriptions, including contract information, work narratives, financial details, and relevant contacts. Compliance with the Trade Agreement Act and Buy American Act is mandatory, along with proof of manufacturing or certified reseller status. This RFP is part of the federal initiative to ensure a reliable supply chain for essential pharmaceuticals, focusing on quality, compliance, and past performance evaluation to select qualified vendors effectively.
Jan 3, 2025, 4:04 PM UTC
The document pertains to RFP 75A50325R00003 for Bulk Pharma Group B, outlining a business template required for pharmaceutical product proposals. It requests detailed information from offerors regarding various pharmaceutical items, including Acyclovir, Doxycycline, Levophed, Meropenem, Sodium Chloride, and Sterile Water, specifying unit quantities and pricing for multiple option years. The template mandates the completion of fields such as total quantities provided by the U.S. Government (USG) for each option year, manufacturing details like NDC numbers, vendor's pricing for each product, and extended price calculations. The purpose of this RFP is to procure essential injectable medications from qualified suppliers, ensuring that bids can be compared across submissions for suitability and cost-effectiveness. This structured approach facilitates transparency and compliance with government procurement standards while providing a clear breakdown of expected quantities and pricing for evaluation by the awarding agency.
Jan 3, 2025, 4:04 PM UTC
The document is a question and answer sheet associated with the Request for Proposal (RFP) identified as Solicitation No. 75A50325R00003. It serves as a platform for contractors to submit inquiries about the RFP. Each entry provides sections for contractors' questions, detailing references to specific sections, paragraphs, and pages of the solicitation language. The government's responses are consolidated and provided directly below each question, indicating continuity in communication regarding the requirements and clarifications needed by potential vendors. The structure allows for systematic tracking of questions and responses, ensuring transparency and thorough understanding of the solicitation process. Overall, this Q&A sheet is a vital component of the RFP process, facilitating clear dialogue between the government and contractors to refine proposals and enhance compliance with outlined solicitations.
Jan 3, 2025, 4:04 PM UTC
The section 52.212-3 outlines the Offeror Representations and Certifications specific to commercial products and services, primarily emphasizing compliance with government contracting requirements. It requires Offerors to complete necessary certifications electronically through the System for Award Management (SAM). Key definitions are provided, including those for economically disadvantaged businesses, prohibited child labor scenarios, and ownership classifications such as small business and veteran-owned businesses. The document mandates disclosures related to federal tax liabilities, previous contract compliance, and restrictions on operations relating to Sudan and Iran. Additionally, certifications for products' compliance with the Buy American Act and trade agreement regulations are to be included. The provisions underscore various contextual business classifications, mirroring regulations observed in government RFPs and grants. The purpose of this document is to ensure that entities engaging in federal contracts adhere to specific ethical, legal, and operational standards, fostering transparency and accountability within government procurement processes.
The document appears to be related to federal and state procurement processes, specifically Request for Proposals (RFPs) and grants. It likely contains various details about initiatives aimed at soliciting contractor services or funding. Key topics may involve project objectives, eligibility criteria, application processes, deadlines, budget considerations, and reporting requirements. The structure of the document could include sections delineating the scope of work, evaluation criteria, and terms of agreement, thereby guiding organizations on how to respond effectively. Overall, the document emphasizes the importance of compliance with federal regulations and local laws in pursuit of funding opportunities. It underscores the federal government's commitment to transparent contracting, ensuring that selected proposals align with public policy goals and community needs. Stakeholders must carefully assess the outlined requirements and tailor their proposals to meet the specified objectives while adhering to all stipulated guidelines and deadlines.
Lifecycle
Title
Type
Bulk Pharma Group B
Currently viewing
Combined Synopsis/Solicitation
Similar Opportunities
6505--Metformin IR Tablets
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Metformin HCL IR Tablets as part of its pharmaceutical prime vendor programs, which also serve the Department of Defense (DoD). Offerors are required to submit pricing for various bottle sizes and quantities, ensure compliance with FDA regulations, and adhere to the Drug Supply Chain Security Act (DSCSA), including providing a unique National Drug Code (NDC) for each product. This procurement is crucial for maintaining a reliable source of pharmaceutical products, ensuring consistent availability and pricing while meeting federal regulatory standards. Interested parties should contact Senior Contract Specialist Teresa Hussain at teresa.hussain@va.gov for further details, and proposals must be submitted in accordance with the outlined requirements within the specified timeframe.
6505--Buspirone RFP
Buyer not available
The Department of Veterans Affairs is soliciting proposals for the supply of Buspirone HCL, a pharmaceutical product essential for the healthcare services provided to veterans. The procurement process requires vendors to submit pricing for multiple line items covering a base year and four option years, ensuring compliance with the Drug Supply Chain Security Act and FDA Good Manufacturing Practices. This contract aims to maintain a reliable supply chain for federal healthcare providers, including the VA, Department of Defense, and Indian Health Service, while securing volume-based pricing for the necessary pharmaceuticals. Interested vendors must submit their offers by May 8, 2025, at 2:30 PM CT, and can direct inquiries to Contract Specialist Amber Zavala at amber.zavala@va.gov.
Valsartan/Hydrochlorothiazide Tablets
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Valsartan/Hydrochlorothiazide Tablets, which includes various dosages in 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are essential for treating hypertension and heart failure, and will serve customers including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in May 2025. Interested parties can reach out to Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for inquiries, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
6505--Acyclovir Capsules (VA-25-00048078)
Buyer not available
The Department of Veterans Affairs is seeking proposals for the procurement of Acyclovir Capsules, specifically 200MG capsules in two packaging sizes, to support the healthcare needs of veterans. The solicitation includes two line items: Line Item 1 requires 3,256 bottles of 100 capsules per bottle, and Line Item 2 requests 15,475 bottles of 500 capsules per bottle, with the same quantities needed for the base year and each of the four option years. This procurement is crucial for ensuring a reliable supply of essential pharmaceuticals for veterans, emphasizing the importance of compliance and competition within the pharmaceutical supply chain. Interested suppliers must submit their pricing proposals by May 1, 2025, and can contact Contracting Officer Andrew Cazares at andrew.cazaeres@va.gov or (708) 786-4990 for further details.
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Buyer not available
The Department of Defense (DoD) is seeking pharmaceutical manufacturers to participate in a Request for Quotation (RFQ) for the Uniform Formulary Blanket Purchase Agreement (UF BPA) and the Uniform Formulary Additional Discount Program (UF ADP) as part of its integrated pharmacy benefits program for the Military Health System (MHS). The procurement aims to evaluate and select pharmaceutical agents based on their clinical and cost-effectiveness for inclusion in the DoD Uniform Formulary, with specific focus on newly approved drugs in categories such as analgesics, antihemophilic agents, benign prostatic hyperplasia agents, and nephrology agents. Interested vendors must submit their quotes by May 15, 2025, and participate in a pre-quotation teleconference scheduled for May 6, 2025, with further details available in the attached RFQ document. For inquiries, vendors can contact Julia Trang at julia.n.trang.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
Fluticasone Propionate
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Fluticasone Propionate, a pharmaceutical product essential for respiratory treatments. The procurement will include various formulations of Fluticasone Propionate combined with Salmeterol, specifically in HFA inhalers, and aims to establish a national supply source for the Department of Defense, Indian Health Service, and Bureau of Prisons customers. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base period and four one-year options, with the solicitation expected to be posted in May 2025. Interested parties can direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or call 445-737-5419, and are encouraged to set up automated notifications for updates on the solicitation.
Rabeprazole Sodium DR
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Rabeprazole Sodium DR 20MG Tablets. This procurement aims to fulfill the pharmaceutical needs of military personnel, emphasizing compliance with federal acquisition regulations and ethical conduct in contractor performance. Interested vendors must submit their proposals via the DLA's Internet Bid Board System (DIBBS) by May 15, 2025, and are encouraged to reach out to primary contact Trong Nguyen at Trong.Nguyen@dla.mil or secondary contact Jason Wray at jason.wray@dla.mil for further inquiries.
6505--Topiramate Tablets (VA-25-00047941)
Buyer not available
The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Topiramate Tablets under the contract number VA-25-00047941. This procurement aims to ensure a consistent supply of essential pharmaceuticals, including Topiramate and Tadalafil, to support various government healthcare programs, including the Department of Defense and the Indian Health Service. Offerors are required to comply with the Drug Supply Chain Security Act (DSCSA), including specific packaging, labeling standards, and rigorous cGMP compliance, while submitting pricing for the base year and four option years. Interested parties should contact Contract Specialist Billy Fong at Billy.Fong@va.gov for further details and to participate in the proposal submission process.
2 PAM Autoinjectors
Buyer not available
The Department of Health and Human Services, specifically the Biomedical Advanced Research and Development Authority (BARDA), is seeking market information regarding the development and manufacturing of 2-PAM (Pralidoxime) autoinjectors intended for the treatment of organophosphate poisoning, including exposure to nerve agents. The objective is to gather data on the capabilities of businesses to produce FDA-approved autoinjectors, with a requirement to manufacture up to 2 million units that meet Emergency Use Authorization standards by 2027. This initiative is crucial for ensuring effective public health responses to chemical, biological, radiological, and nuclear (CBRN) threats through adequate medical countermeasures. Interested parties must submit their responses, including business and technical representations, by May 14, 2025, and can contact Kevin Dean at kevin.dean1@hhs.gov or Erin Greninger at erin.greninger@hhs.gov for further information.
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Buyer not available
The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.